David Bredt
Chief Scientific Officer · Rapport Therapeutics, Inc.
- 2025
- Feb 20, 2026
- 10
Other insiders active in the same stocks
Insiders who reported open-market trades in the last 12 months at the companies David Bredt files at. Multiple unrelated insiders buying the same stock within a short window, cluster buying, has historically been one of the strongest Form 4 signals.
- Third Rock Ventures V, L.P. - $34.39M in RAPP purchases and sales in the last 12 months
- Abraham Ceesay - $6.21M in RAPP purchases and sales in the last 12 months
- Krishnaswamy Yeleswaram - $4.46M in RAPP purchases and sales in the last 12 months
- Cheryl Gault - $1.24M in RAPP purchases and sales in the last 12 months
More insiders (A-Z)
Browse nearby insider profiles in alphabetical order.
Frequently asked questions
Who is David Bredt?
David Bredt is a corporate insider, tracked as Chief Scientific Officer of Rapport Therapeutics, Inc. (RAPP). InsiderAlpha holds 10 primary Form 4 filings for them, the earliest from 2025, updated as new SEC EDGAR filings are processed.
When did David Bredt last file a Form 4?
The most recent primary Form 4 on record is dated 20 February 2026, one of 10 filings going back to 2025.
Has David Bredt been buying or selling stock?
Recorded transactions: 0 open-market purchases and 17 open-market sales ($1.81M) across all tracked filings.
